Katsuyuki Aozasa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Katsuyuki Aozasa has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Shin-Ichi Nakatsuka
Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan
8 shared publications Yasuhiko Tomita
Department of Pathology, Osaka University Graduate School of Medicine, 2–2 Yamadaoka, Suita, Osaka 565–0871
6 shared publicationsHideaki Miwa
Department of Pathology, Osaka University Graduate School of Medicine, 2–2 Yamadaoka, Suita, Osaka 565–0871
5 shared publicationsMasahiko Ohsawa
Department of Pathology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
5 shared publicationsHiroyuki Kanno
Department of Pathology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
4 shared publicationsShizuo Kojya
Department of Otorhinolaryngology, Graduate School of Medicine, University of Ryukyus, Okinawa, Japan
4 shared publications
Latest Publications
- 9 February 2012
- Published by Wiley in Histopathology
- Vol. 60 (6) , 924-932
Diffuse large B cell lymphoma with an interfollicular pattern of proliferation shows a favourable prognosis: a study of the Osaka Lymphoma Study Group
Wada N, Zaki M A A, Kohara M, Ogawa H, Sugiyama H, Nomura S, Matsumura I, Hino M, Kanakura Y, Inagaki H, Morii E & Aozasa K (2012) Histopathology 60, 924–932 Diffuse large B cell lymphoma with an interfollicular pattern of proliferation shows a favourable prognosis: a study of the Osaka Lymphoma Study GroupAims: ]Diffuse large B cell lymphoma (DLBCL) occasionally shows an interfollicular pattern of proliferation (DLBCL‐IF) preserving lymphoid follicles. In this study, clinicopathological findings in 31 cases of DLBCL‐IF were analysed.Methods and results: The study group comprised 20 males and 11 females, with ages ranging from 41 to 87 (median 69) years. The primary site was lymph node in 25 cases, and unknown in six due to advanced stage at diagnosis. Eight cases were clinical Stage I, 10 were Stage II, four Stage III, and nine Stage IV. A polymorphous pattern of proliferation containing large B cells and inflammatory cells was found in about 60% of cases. The overall survival rate of the DLBCL‐IF patients was better than that of a DLBCL control group (log‐rank test; P < 0.05). Multivariate analysis revealed that an interfollicular pattern of proliferation showed marginal significance for favourable prognosis (P = 0.069). Immunohistochemical double staining with antibodies for HLA‐DR/CD68 (markers for M1‐tumour‐associated macrophage [M1‐TAM]) or CD163/CD68 (M2‐TAM) revealed that all DLBCL‐IF patients with a low M2 count were alive at the end of observation.Conclusions: These findings suggest that DLBCL‐IF is a clinicopathological entity distinct from ordinary DLBCL. The possible origin of tumour cells in DLBCL‐IF from marginal zone B cells is discussed.
- 9 February 2012
- Published by Wiley in Histopathology
- Vol. 60 (6) , 924-932
Diffuse large B cell lymphoma with an interfollicular pattern of proliferation shows a favourable prognosis: a study of the Osaka Lymphoma Study Group
Wada N, Zaki M A A, Kohara M, Ogawa H, Sugiyama H, Nomura S, Matsumura I, Hino M, Kanakura Y, Inagaki H, Morii E & Aozasa K (2012) Histopathology 60, 924–932 Diffuse large B cell lymphoma with an interfollicular pattern of proliferation shows a favourable prognosis: a study of the Osaka Lymphoma Study GroupAims: ]Diffuse large B cell lymphoma (DLBCL) occasionally shows an interfollicular pattern of proliferation (DLBCL‐IF) preserving lymphoid follicles. In this study, clinicopathological findings in 31 cases of DLBCL‐IF were analysed.Methods and results: The study group comprised 20 males and 11 females, with ages ranging from 41 to 87 (median 69) years. The primary site was lymph node in 25 cases, and unknown in six due to advanced stage at diagnosis. Eight cases were clinical Stage I, 10 were Stage II, four Stage III, and nine Stage IV. A polymorphous pattern of proliferation containing large B cells and inflammatory cells was found in about 60% of cases. The overall survival rate of the DLBCL‐IF patients was better than that of a DLBCL control group (log‐rank test; P < 0.05). Multivariate analysis revealed that an interfollicular pattern of proliferation showed marginal significance for favourable prognosis (P = 0.069). Immunohistochemical double staining with antibodies for HLA‐DR/CD68 (markers for M1‐tumour‐associated macrophage [M1‐TAM]) or CD163/CD68 (M2‐TAM) revealed that all DLBCL‐IF patients with a low M2 count were alive at the end of observation.Conclusions: These findings suggest that DLBCL‐IF is a clinicopathological entity distinct from ordinary DLBCL. The possible origin of tumour cells in DLBCL‐IF from marginal zone B cells is discussed.
- 1 March 2011
- Published by Wiley in European Journal of Haematology
- Vol. 86 (5) , 412-419
Presence of B‐cell clones in T‐cell lymphoma
Objectives: The presence of B‐cell clones in 76 cases with peripheral T‐cell lymphoma (PTCL) and precursor T‐lymphoblastic lymphoma (T‐LBL) and its correlation with Epstein–Barr virus (EBV) was studied.Methods: DNA was extracted from paraffin sections and/or fresh‐frozen samples and then used for clonality analysis using a modified BIOMED‐2 polymerase chain reaction (PCR)‐based method.Results: T‐ and B‐cell clones were detected in 59 (77.6%) and 14 (18.4%) of 76 patients, respectively: 90% and 30% of cases with PTCL, not otherwise specified, 76.4% and 17.6% of cases with angioimmunoblastic T‐cell lymphoma, 77% and 7.6% of cases with adult T‐cell lymphoma, 50% and 0% of cases with anaplastic large T‐cell lymphoma, 62.5% and 12.5% of cases with T‐LBL, and 50% and 0% of cases with intestinal T‐cell lymphoma, respectively. Histological and immunohistochemical analyses revealed the presence of large B cells in lesional tissues, which were occasionally monoclonal. The presence of B‐cell clones was highly associated with EBV positivity, as revealed by in situ hybridization. In two cases that were evaluated by serial histological and molecular examination, EBV‐positive cells persisted in one and disappeared in the other.Conclusions: These findings suggest a role for EBV in the evolution of B‐cell clones in T‐cell lymphomas.
- 1 March 2011
- Published by Wiley in European Journal of Haematology
- Vol. 86 (5) , 412-419
Presence of B‐cell clones in T‐cell lymphoma
Objectives: The presence of B‐cell clones in 76 cases with peripheral T‐cell lymphoma (PTCL) and precursor T‐lymphoblastic lymphoma (T‐LBL) and its correlation with Epstein–Barr virus (EBV) was studied.Methods: DNA was extracted from paraffin sections and/or fresh‐frozen samples and then used for clonality analysis using a modified BIOMED‐2 polymerase chain reaction (PCR)‐based method.Results: T‐ and B‐cell clones were detected in 59 (77.6%) and 14 (18.4%) of 76 patients, respectively: 90% and 30% of cases with PTCL, not otherwise specified, 76.4% and 17.6% of cases with angioimmunoblastic T‐cell lymphoma, 77% and 7.6% of cases with adult T‐cell lymphoma, 50% and 0% of cases with anaplastic large T‐cell lymphoma, 62.5% and 12.5% of cases with T‐LBL, and 50% and 0% of cases with intestinal T‐cell lymphoma, respectively. Histological and immunohistochemical analyses revealed the presence of large B cells in lesional tissues, which were occasionally monoclonal. The presence of B‐cell clones was highly associated with EBV positivity, as revealed by in situ hybridization. In two cases that were evaluated by serial histological and molecular examination, EBV‐positive cells persisted in one and disappeared in the other.Conclusions: These findings suggest a role for EBV in the evolution of B‐cell clones in T‐cell lymphomas.
- 22 December 2010
- Published by Wiley in Journal of Medical Virology
- Vol. 83 (2) , 317-321
Epstein–barr virus in diffuse large B‐Cell lymphoma in immunocompetent patients in Japan is as low as in Western Countries
According to previous reports, the frequency of Epstein–Barr virus (EBV) positivity in diffuse large B‐cell lymphoma is higher in East Asia (approximately 9%) than in Western countries. The presence of the EBV genome was examined in diffuse large B‐cell lymphoma patients registered with the Osaka Lymphoma Study Group (OLSG) in Osaka, Japan, situated in East Asia. The EBV‐positive rate was examined with in situ hybridization (ISH) in 484 immunocompetent diffuse large B‐cell lymphoma patients registered with OLSG. The male‐to‐female ratio was 1.29, with ages ranging from 16 to 95 (median, 68) years. ISH with EBV‐encoded small RNAs (EBER) probes revealed positive signals in the nuclei of tumor cells: the frequency of positively stained cells among all tumor cells was almost none in 458 cases, 5–10% in 5, 10–20% in 5, 20–50% in 11, and >50% in 5. When the frequency was >20% or >50%, the EBV‐positive rate in the present series (3.3% or 1.0%) was rather similar to that reported in Western cases. Careful evaluation of patient backgrounds, including age distribution, type of lymphomas, exclusion of immunocompromised patients, and establishment of definite criteria for EBV positivity (>20%, >50%, or almost all tumor cells) are essential in comparing geographical differences. J. Med. Virol. 83:317–321, 2011.
- 22 December 2010
- Published by Wiley in Journal of Medical Virology
- Vol. 83 (2) , 317-321
Epstein–barr virus in diffuse large B‐Cell lymphoma in immunocompetent patients in Japan is as low as in Western Countries
According to previous reports, the frequency of Epstein–Barr virus (EBV) positivity in diffuse large B‐cell lymphoma is higher in East Asia (approximately 9%) than in Western countries. The presence of the EBV genome was examined in diffuse large B‐cell lymphoma patients registered with the Osaka Lymphoma Study Group (OLSG) in Osaka, Japan, situated in East Asia. The EBV‐positive rate was examined with in situ hybridization (ISH) in 484 immunocompetent diffuse large B‐cell lymphoma patients registered with OLSG. The male‐to‐female ratio was 1.29, with ages ranging from 16 to 95 (median, 68) years. ISH with EBV‐encoded small RNAs (EBER) probes revealed positive signals in the nuclei of tumor cells: the frequency of positively stained cells among all tumor cells was almost none in 458 cases, 5–10% in 5, 10–20% in 5, 20–50% in 11, and >50% in 5. When the frequency was >20% or >50%, the EBV‐positive rate in the present series (3.3% or 1.0%) was rather similar to that reported in Western cases. Careful evaluation of patient backgrounds, including age distribution, type of lymphomas, exclusion of immunocompromised patients, and establishment of definite criteria for EBV positivity (>20%, >50%, or almost all tumor cells) are essential in comparing geographical differences. J. Med. Virol. 83:317–321, 2011.
- Open Access
- 25 October 2006
- Published by Wiley in International Journal of Cancer
- Vol. 120 (2) , 406-410
Life‐style and environmental factors in the development of nasal NK/T‐cell lymphoma: A case–control study in East Asia
Cases of nasal NK/T‐cell lymphoma (NKTCL) occur occasionally in Asian and Latin American countries but rarely in Western countries. The etiological role of life‐style and environmental factors in nasal NKTCL was investigated. Five university hospitals in Japan and one each in Korea and China participated in this study; a total of 88 cases and 305 hospital controls were accrued during 2000–2005. The odds ratio (OR) of NKTCL obtained after adjustments of age, sex and country was 4.15 (95% confidence interval (CI), 1.74–9.87) for farmers, 2.81 (CI, 1.49–5.29) for producers of crops, 4.01 (CI, 1.99–8.09) for pesticide users, 11.65 (CI, 1.17–115.82) for residents near garbage burning plants, 2.95 (CI, 1.25–6.95) for former drinkers, and 0.49 (CI, 0.23–1.04) for current smokers. The ORs for crop producers, who minimized their exposure to pesticides by using gloves and glasses, and sprinkling downwind at the time of pesticide use, were 3.30 (95% CI, 1.28–8.54), 1.18 (95% CI, 0.11–12.13) and 2.20 (95% CI, 0.88–5.53), respectively, which were lower than those for producers who did not take these precautions. Exposure to pesticides and chemical solvents could be causative of NKTCL. Taken together, life‐style and environmental factors might be risk factors for NKTCL.
- 25 October 2006
- Published by Wiley in International Journal of Cancer
- Vol. 120 (2) , 406-410
Open AccessLife‐style and environmental factors in the development of nasal NK/T‐cell lymphoma: A case–control study in East Asia
Cases of nasal NK/T‐cell lymphoma (NKTCL) occur occasionally in Asian and Latin American countries but rarely in Western countries. The etiological role of life‐style and environmental factors in nasal NKTCL was investigated. Five university hospitals in Japan and one each in Korea and China participated in this study; a total of 88 cases and 305 hospital controls were accrued during 2000–2005. The odds ratio (OR) of NKTCL obtained after adjustments of age, sex and country was 4.15 (95% confidence interval (CI), 1.74–9.87) for farmers, 2.81 (CI, 1.49–5.29) for producers of crops, 4.01 (CI, 1.99–8.09) for pesticide users, 11.65 (CI, 1.17–115.82) for residents near garbage burning plants, 2.95 (CI, 1.25–6.95) for former drinkers, and 0.49 (CI, 0.23–1.04) for current smokers. The ORs for crop producers, who minimized their exposure to pesticides by using gloves and glasses, and sprinkling downwind at the time of pesticide use, were 3.30 (95% CI, 1.28–8.54), 1.18 (95% CI, 0.11–12.13) and 2.20 (95% CI, 0.88–5.53), respectively, which were lower than those for producers who did not take these precautions. Exposure to pesticides and chemical solvents could be causative of NKTCL. Taken together, life‐style and environmental factors might be risk factors for NKTCL.
- 1 October 2004
- Published by Wiley in Cancer Science
- Vol. 95 (10) , 828-834
Distinct pattern of gene expression in pyothorax‐associated lymphoma (PAL), a lymphoma developing in long‐standing inflammation
Pyothorax‐associated lymphoma (PAL) is a unique lymphoma developing in the pleural cavity after long‐standing pyothorax. They are diffuse large B‐cell lymphomas (DLBCLs), frequently with immunoblastic morphology, and show a strong association with Epstein‐Barr virus (EBV) infection. In this study, cDNA microarray analysis was performed in six cases with PAL and 12 with nodal DLBCL. Among 5516 informative genes, 348 displayed more than 2‐fold difference (higher or lower) of expression level between PAL and nodal DLBCL (P>0.001). These genes are known to be involved in apoptosis, interferon response, and signal transduction. One of the most differentially expressed genes, IFI27 (interferon‐α‐inducible protein 27) was subjected to quantitative RT‐PCR analysis, and increased expression of IFI27 was confirmed. Over‐expression of IFI27 was also found in cell lines derived from PAL, but not in other lymphoid cell lines. This study shows that PAL is a distinctive subtype of DLBCL not only in its clinical presentation, but also in its molecular profile.
- 1 October 2004
- Published by Wiley in Cancer Science
- Vol. 95 (10) , 828-834
Distinct pattern of gene expression in pyothorax‐associated lymphoma (PAL), a lymphoma developing in long‐standing inflammation
Pyothorax‐associated lymphoma (PAL) is a unique lymphoma developing in the pleural cavity after long‐standing pyothorax. They are diffuse large B‐cell lymphomas (DLBCLs), frequently with immunoblastic morphology, and show a strong association with Epstein‐Barr virus (EBV) infection. In this study, cDNA microarray analysis was performed in six cases with PAL and 12 with nodal DLBCL. Among 5516 informative genes, 348 displayed more than 2‐fold difference (higher or lower) of expression level between PAL and nodal DLBCL (P>0.001). These genes are known to be involved in apoptosis, interferon response, and signal transduction. One of the most differentially expressed genes, IFI27 (interferon‐α‐inducible protein 27) was subjected to quantitative RT‐PCR analysis, and increased expression of IFI27 was confirmed. Over‐expression of IFI27 was also found in cell lines derived from PAL, but not in other lymphoid cell lines. This study shows that PAL is a distinctive subtype of DLBCL not only in its clinical presentation, but also in its molecular profile.
- Open Access
- 28 October 2003
- Published by Wiley in International Journal of Cancer
- Vol. 108 (3) , 443-449
Lymphoproliferative disorders in autoimmune diseases in Japan: Analysis of clinicopathological features and Epstein‐Barr virus infection
Lymphoproliferative disorders (LPD) occasionally develop in individuals with immune deficiencies such as immunosuppressive conditions and autoimmune diseases (AID). In our study, the clinicopathologic features and virus status were analyzed in 53 cases with LPD developing in rheumatoid arthritis (RA) and other AID. AID in only 4 of 53 patients had been treated with some sort of immunosuppressive therapy, including methotrexate. Median age at the diagnosis of LPD in AID was 60 years old with marked female predominance (M/F = 0.4). The median interval between the onset of AID and LPD development was 45 months, and longer in RA patients than in other AID (p< 0.01). The primary site of lymphoma was nodal in 21 cases and extra‐nodal in 24, with clinical Stage I in 17, II in 5, III in 13, and IV in 13. Immunohistochemistry showed that 39 cases were B cell type, 10 were T cell type and 4 were Hodgkin lymphoma (HL). Then majority of B cell cases were diffuse large B cell lymphomas, and 2 were diffuse polymorphic type. EBER‐1in situhybridization for Epstein‐Barr virus (EBV) showed positive signals in tumor cells in 16 of 53 (30.2%) cases. The EBV‐positive rate in T cell LPD (70%) was much higher than that in B cell LPD (12.8%) (p< 0.01). All 4 cases of HL were EBV‐positive. Immunohistochemistry showed a latency II pattern of EBV infection (LMP‐1+and EBNA‐2−). Five‐year overall survival rate was 33%. Multivariate analysis showed that only type of AID was an independent factor for survival of patients,i.e., LPD in RA showed the most favorable prognosis. In conclusion, LPD in AID generally shared common features with sporadic LPD except for a much higher EBV‐positive rate in T cell LPD.
- 28 October 2003
- Published by Wiley in International Journal of Cancer
- Vol. 108 (3) , 443-449
Open AccessLymphoproliferative disorders in autoimmune diseases in Japan: Analysis of clinicopathological features and Epstein‐Barr virus infection
Lymphoproliferative disorders (LPD) occasionally develop in individuals with immune deficiencies such as immunosuppressive conditions and autoimmune diseases (AID). In our study, the clinicopathologic features and virus status were analyzed in 53 cases with LPD developing in rheumatoid arthritis (RA) and other AID. AID in only 4 of 53 patients had been treated with some sort of immunosuppressive therapy, including methotrexate. Median age at the diagnosis of LPD in AID was 60 years old with marked female predominance (M/F = 0.4). The median interval between the onset of AID and LPD development was 45 months, and longer in RA patients than in other AID (p< 0.01). The primary site of lymphoma was nodal in 21 cases and extra‐nodal in 24, with clinical Stage I in 17, II in 5, III in 13, and IV in 13. Immunohistochemistry showed that 39 cases were B cell type, 10 were T cell type and 4 were Hodgkin lymphoma (HL). Then majority of B cell cases were diffuse large B cell lymphomas, and 2 were diffuse polymorphic type. EBER‐1in situhybridization for Epstein‐Barr virus (EBV) showed positive signals in tumor cells in 16 of 53 (30.2%) cases. The EBV‐positive rate in T cell LPD (70%) was much higher than that in B cell LPD (12.8%) (p< 0.01). All 4 cases of HL were EBV‐positive. Immunohistochemistry showed a latency II pattern of EBV infection (LMP‐1+and EBNA‐2−). Five‐year overall survival rate was 33%. Multivariate analysis showed that only type of AID was an independent factor for survival of patients,i.e., LPD in RA showed the most favorable prognosis. In conclusion, LPD in AID generally shared common features with sporadic LPD except for a much higher EBV‐positive rate in T cell LPD.
- 22 August 2002
- Published by Wiley in The Prostate
- Vol. 52 (4) , 279-287
Postatrophic hyperplasia of the prostate in Japan: Histologic and immunohistochemical features and p53 gene mutation analysis
BACKGROUND: Postatrophic hyperplasia (PAH) is one of the patterns of prostatic atrophy but has been regarded as a precursor of prostatic cancer (PCA) because of its possible increase in proliferative activity compared with simple atrophy and morphologic mimicry of PCA.METHODS: Radical prostatectomy specimens obtained from 28 patients with PCA were analyzed by histologic and immunohistochemical methods by using 34βE12 and Ki‐67 as primary antibodies. Tissue from PAH, PCA, high‐grade prostatic intraepithelial neoplasia (HGPIN), a possible precursor of PCA, and benign hyperplasia were microdissected and p53 gene mutations were examined by the polymerase chain reaction–single strand conformation polymorphism method followed by direct sequencing.RESULTS: Histologically, PAH consists of compactly arranged small acini with irregular atrophic‐appearing contours, mimicking PCA. PAH lesions were detected in 7 (25%) of 28 cases with PCA: multifocal in 6 of 7 (85.7%) cases, maximum size of lesions ranged from 0.3 to 2.3 mm. Mild nuclear enlargement and small nucleoli were observed in all cases. Capsular or perineural invasion, crystalloids, and mitotic figures were not found in any case. Inflammatory changes and fibrosis near PAH were found in 100% and 71% of cases, respectively. PAH involved non‐transition zone in all cases and occasionally involved transition zone. Forty‐three percent of PAH lesions were in proximity (p53 mutations in PAH lesions was 5.3%, which was similar to that in HGPIN lesions (4.2%). Benign glands never showed mutations.CONCLUSION: These findings suggested that PAH might be a precursor for PCA. Prostate 52: 279–287, 2002.
- 22 August 2002
- Published by Wiley in The Prostate
- Vol. 52 (4) , 279-287
Postatrophic hyperplasia of the prostate in Japan: Histologic and immunohistochemical features and p53 gene mutation analysis
BACKGROUND: Postatrophic hyperplasia (PAH) is one of the patterns of prostatic atrophy but has been regarded as a precursor of prostatic cancer (PCA) because of its possible increase in proliferative activity compared with simple atrophy and morphologic mimicry of PCA.METHODS: Radical prostatectomy specimens obtained from 28 patients with PCA were analyzed by histologic and immunohistochemical methods by using 34βE12 and Ki‐67 as primary antibodies. Tissue from PAH, PCA, high‐grade prostatic intraepithelial neoplasia (HGPIN), a possible precursor of PCA, and benign hyperplasia were microdissected and p53 gene mutations were examined by the polymerase chain reaction–single strand conformation polymorphism method followed by direct sequencing.RESULTS: Histologically, PAH consists of compactly arranged small acini with irregular atrophic‐appearing contours, mimicking PCA. PAH lesions were detected in 7 (25%) of 28 cases with PCA: multifocal in 6 of 7 (85.7%) cases, maximum size of lesions ranged from 0.3 to 2.3 mm. Mild nuclear enlargement and small nucleoli were observed in all cases. Capsular or perineural invasion, crystalloids, and mitotic figures were not found in any case. Inflammatory changes and fibrosis near PAH were found in 100% and 71% of cases, respectively. PAH involved non‐transition zone in all cases and occasionally involved transition zone. Forty‐three percent of PAH lesions were in proximity (p53 mutations in PAH lesions was 5.3%, which was similar to that in HGPIN lesions (4.2%). Benign glands never showed mutations.CONCLUSION: These findings suggested that PAH might be a precursor for PCA. Prostate 52: 279–287, 2002.
- 1 August 2002
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 93 (8) , 894-901
Microarray Analysis of Gene‐expression Profiles in Diffuse Large B‐cell Lymphoma: Identification of Genes Related to Disease Progression
To identify genes that are associated with progression of malignant lymphoma, the expression profiles of 18 432 genes were analyzed in diffuse large B‐cell lymphomas at early (stages I and II, 6 cases) and advanced stages (stages III and IV, 9 cases) by means of cDNA microarrays. By comparing expression profiles between localized and advanced lymphomas, a number of genes that were differentially expressed were identified: 48 genes with increased expression and 30 genes with reduced expression in advanced‐stage diffuse large B‐cell lymphomas. Increased expression of MPHOSPH1, RUVBL1, CHN2, PSA and CDC10 genes, and reduced expression of COL1A2, COL4A1, FBLN5, CLECSF6, MIC2, CAV1 and S100A10 genes in the advanced lymphoma group were confirmed by semi‐quantitative reverse transcription‐PCR. RUVBL1 and PSA expression was further confirmed by real‐tune quantitative PCR, whose results paralleled the microarray data. The highly expressed genes encode proteins that promote cell proliferation and the genes with reduced expression encode adhesion proteins and target protein for cytotoxic T‐lymphocytes. These findings suggested that analysis with cDNA microarrays is a useful approach for identifying genes related to tumor progression and their products could be potential tumor markers or disease‐specific targets for anti‐tumor therapy.
- 1 August 2002
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 93 (8) , 894-901
Microarray Analysis of Gene‐expression Profiles in Diffuse Large B‐cell Lymphoma: Identification of Genes Related to Disease Progression
To identify genes that are associated with progression of malignant lymphoma, the expression profiles of 18 432 genes were analyzed in diffuse large B‐cell lymphomas at early (stages I and II, 6 cases) and advanced stages (stages III and IV, 9 cases) by means of cDNA microarrays. By comparing expression profiles between localized and advanced lymphomas, a number of genes that were differentially expressed were identified: 48 genes with increased expression and 30 genes with reduced expression in advanced‐stage diffuse large B‐cell lymphomas. Increased expression of MPHOSPH1, RUVBL1, CHN2, PSA and CDC10 genes, and reduced expression of COL1A2, COL4A1, FBLN5, CLECSF6, MIC2, CAV1 and S100A10 genes in the advanced lymphoma group were confirmed by semi‐quantitative reverse transcription‐PCR. RUVBL1 and PSA expression was further confirmed by real‐tune quantitative PCR, whose results paralleled the microarray data. The highly expressed genes encode proteins that promote cell proliferation and the genes with reduced expression encode adhesion proteins and target protein for cytotoxic T‐lymphocytes. These findings suggested that analysis with cDNA microarrays is a useful approach for identifying genes related to tumor progression and their products could be potential tumor markers or disease‐specific targets for anti‐tumor therapy.
- 1 April 2002
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 93 (4) , 411-416
Enhanced Expression of Neuron-specific Enolase (NSE) in Pyothorax-associated Lymphoma (PAL)
Pyothorax‐associated lymphoma (PAL) is a B‐cell lymphoma of mostly large cell type developing in the pleural cavity of patients with long‐standing pyothorax. Neuron‐specific enolase (NSE) is an enolase comprising γ subunit and is located at high levels in neuronal and neuroendocrine cells, together with their neoplasias. Expression of NSE at protein and mRNA levels was examined in PAL and other types (non‐PAL) of non‐Hodgkin's lymphomas. In PAL, serum levels of NSE were elevated (5.32 to 168.0, mean 42.6 ng/ml) and tended to decrease after incisional biopsy followed by chemotherapy (2.38 to 195.5, mean 34.1 ng/ml). Two cell lines established from two cases of PAL produced and secreted NSE in the culture medium. Immunohistochemistry revealed that the positive rate for NSE staining in PAL (10 of 14 cases, 71.4%) was significantly higher than that in non‐PAL cases (6 of 38 cases, 15.8%) (P<0.01). RT‐PCR analysis showed that the expression levels of NSE mRNA in two cell lines and a biopsy sample from PAL were rather similar to those of the control samples from non‐neoplastic lymph nodes. These findings suggest the posttranscriptional regulation of NSE in PAL. Thus, an elevation of serum NSE level in patients with chronic pyothorax may be an indicator of PAL development.
- 1 April 2002
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 93 (4) , 411-416
Enhanced Expression of Neuron-specific Enolase (NSE) in Pyothorax-associated Lymphoma (PAL)
Pyothorax‐associated lymphoma (PAL) is a B‐cell lymphoma of mostly large cell type developing in the pleural cavity of patients with long‐standing pyothorax. Neuron‐specific enolase (NSE) is an enolase comprising γ subunit and is located at high levels in neuronal and neuroendocrine cells, together with their neoplasias. Expression of NSE at protein and mRNA levels was examined in PAL and other types (non‐PAL) of non‐Hodgkin's lymphomas. In PAL, serum levels of NSE were elevated (5.32 to 168.0, mean 42.6 ng/ml) and tended to decrease after incisional biopsy followed by chemotherapy (2.38 to 195.5, mean 34.1 ng/ml). Two cell lines established from two cases of PAL produced and secreted NSE in the culture medium. Immunohistochemistry revealed that the positive rate for NSE staining in PAL (10 of 14 cases, 71.4%) was significantly higher than that in non‐PAL cases (6 of 38 cases, 15.8%) (P<0.01). RT‐PCR analysis showed that the expression levels of NSE mRNA in two cell lines and a biopsy sample from PAL were rather similar to those of the control samples from non‐neoplastic lymph nodes. These findings suggest the posttranscriptional regulation of NSE in PAL. Thus, an elevation of serum NSE level in patients with chronic pyothorax may be an indicator of PAL development.
- 1 March 2002
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 93 (3) , 267-274
Mutations of p53, c‐kit, K‐ras, and β‐Catenin Gene in Non‐Hodgkin's Lymphoma of Adrenal Gland
Malignant lymphoma of the adrenal gland is a rare disease, usually with diffuse large cell morphology and B‐cell immunophenotype, and often associated with Epstein‐Barr virus infection. In this study, mutations of p53, c‐kit, K‐ras, and β‐catenin gene were analyzed in 17 cases (13 males and four females with ages ranging from 25 to 84 years) of such lymphomas by polymerase chain reaction‐single strand conformation polymorphism followed by direct sequencing. Selected exons in each gene, representing hot spots, were analyzed. All 44 mutations detected were single‐nucleotide substitutions and 33 were missense mutations. Nineteen mutations were detected in exon 5 and/or 7 of the p53 gene in nine of 17 cases (52.9%) and 21 in exon 11 and/or 17 of the c‐kit gene in 10 of 14 cases (71.4%). Bilateral adrenal lesions in one case who had not received any adjuvant therapy showed different mutational patterns of the p53 and c‐kit genes, suggesting different clonal evolution of lymphoma between the left and right sides. Mutation at codon 13 of the K‐ras gene was detected in one of 14 cases (7.1%), and in exon 3 of the β‐catenin gene in three of 12 cases (25%). All but one mutation were transition mutations, indicating that some endogenous mutagens act in lymphomagenesis in the adrenal gland. Our results suggest that p53 and c‐kit gene mutations might play a role in adrenal lymphomagenesis.
- 1 March 2002
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 93 (3) , 267-274
Mutations of p53, c‐kit, K‐ras, and β‐Catenin Gene in Non‐Hodgkin's Lymphoma of Adrenal Gland
Malignant lymphoma of the adrenal gland is a rare disease, usually with diffuse large cell morphology and B‐cell immunophenotype, and often associated with Epstein‐Barr virus infection. In this study, mutations of p53, c‐kit, K‐ras, and β‐catenin gene were analyzed in 17 cases (13 males and four females with ages ranging from 25 to 84 years) of such lymphomas by polymerase chain reaction‐single strand conformation polymorphism followed by direct sequencing. Selected exons in each gene, representing hot spots, were analyzed. All 44 mutations detected were single‐nucleotide substitutions and 33 were missense mutations. Nineteen mutations were detected in exon 5 and/or 7 of the p53 gene in nine of 17 cases (52.9%) and 21 in exon 11 and/or 17 of the c‐kit gene in 10 of 14 cases (71.4%). Bilateral adrenal lesions in one case who had not received any adjuvant therapy showed different mutational patterns of the p53 and c‐kit genes, suggesting different clonal evolution of lymphoma between the left and right sides. Mutation at codon 13 of the K‐ras gene was detected in one of 14 cases (7.1%), and in exon 3 of the β‐catenin gene in three of 12 cases (25%). All but one mutation were transition mutations, indicating that some endogenous mutagens act in lymphomagenesis in the adrenal gland. Our results suggest that p53 and c‐kit gene mutations might play a role in adrenal lymphomagenesis.